Speakers:  Christopher Whelan, Senior scientist in the Translational Biology Research Group at Biogen & Simina Ticau, Senior scientist at Alnylam Pharmaceuticals

Original Broadcast date:  Feb 19 2020

Protein biomarkers are increasingly used in clinical research to identify protein signatures that can predict outcomes and responses, effectively stratify patient populations, and provide insights into the biology of disease. Consequently, some pharmaceutical companies are including protein biomarker programs in their drug discovery and development processes, to identify early diagnostic markers of disease that may also advance our understanding of disease biology and potentially identify novel drug targets. In addition, protein biomarkers may serve as essential tools to monitor the effects of therapeutic interventions, even in advance of clinical endpoint observations. Recent developments in multiplex technologies that enable high-throughput analysis of many proteins simultaneously, while using minimal volumes of biological samples, are accelerating the utility of proteomics, and have the potential to support pharmaceutical development across all aspects of the process, from target discovery to postmarket surveillance. This webinar presents two examples that span this range of applications, demonstrating how novel diagnostic biomarkers of early disease development and markers for treatment response in patients can be uncovered.

This webinar covers the following points:

• How multiplex biomarker screening identified signatures to distinguish early and established Alzheimer’s disease
• How a broad screening of over 1,000 proteins identified multiple biomarkers in hATTR amyloidosis patients treated with an RNA interference therapeutic
• Share results comparing correlation data for key protein biomarkers using two different profiling assays.

If you have any questions about Olink, please contact us at info@olink.com.